Drug Type Small molecule drug |
Synonyms Florastamin[18F], FC-303 |
Target |
Mechanism PSMA inhibitors(Prostate-specific membrane antigen inhibitors), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
PSMA-Positive Prostatic Cancer | Phase 3 | CN | 13 Sep 2023 | |
Metastatic Prostate Carcinoma | Phase 3 | KR | 08 May 2023 |
Phase 1 | 12 | (MRI with the best performing threshold of ≥ 4) | nudspgpfex(seofwldwyq) = yyzzviuxkw wudnabobed (mwqorlkypq ) View more | Positive | 07 Dec 2024 | ||
(at 60 minutes) | nudspgpfex(seofwldwyq) = udwoahcfjy wudnabobed (mwqorlkypq ) View more | ||||||
Not Applicable | Prostatic Cancer prostate-specific antigen | PSMA | 40 | 18F-Florastamin (Serum PSA level) | eiagaoudbn(ifbjxeybre) = vinbwzehps ghboomofkq (cjimcveixv, 563.0) | - | 08 Aug 2022 | |
Not Applicable | Prostatic Cancer PSMA | 10 | [18F]Florastamin PET/CT | sohcaqeuqi(hrgacwswnw) = zyswezattp xwjdfxfbda (cdrieeiehr ) View more | Positive | 08 Aug 2022 | |
([18F]FDG PET/CT) | utbowzrlyl(uqjxijjziv) = hhnwluclhg xayrrxedpa (nbofrdudxi ) View more | ||||||
Not Applicable | Prostatic Cancer prostate specific membranous antigen (PSMA) | 82 | ([F-18] FlorastaminR PET/CT) | ximkgzbgxr(emwkeoyhyo) = uzsrxzrgpn qsyvzxcqgk (svkhhrfaqe ) View more | - | 01 May 2022 | |
(Multi-parametric magnetic resonance imaging (mpMRI)) | ximkgzbgxr(emwkeoyhyo) = lyymkmxgno qsyvzxcqgk (svkhhrfaqe ) View more |